Veracyte (NASDAQ:VCYT) is a diagnostic company that focuses on delivering genomic solutions to improve patient outcomes and reduce healthcare costs. It specializes in developing tests for the early detection of cancer and other diseases, providing physicians with actionable insights for patient care. Veracyte's portfolio includes tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis, among others. The company is committed to expanding its product range and enhancing its global presence through strategic partnerships and research advancements. Its operations span from the development and commercialization of its tests to collaborating with biopharmaceutical companies for companion diagnostic development. Veracyte aims to transform the diagnostic landscape by offering precise and minimally invasive tests, thereby enabling better disease management and treatment decisions for patients around the world.